• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项针对小队列帕金森病参与者的益生元纤维干预的开放性、非随机研究。

An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants.

机构信息

Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.

Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.

出版信息

Nat Commun. 2023 Feb 18;14(1):926. doi: 10.1038/s41467-023-36497-x.

DOI:10.1038/s41467-023-36497-x
PMID:36801916
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9938693/
Abstract

A pro-inflammatory intestinal microbiome is characteristic of Parkinson's disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.

摘要

促炎肠道微生物组是帕金森病 (PD) 的特征。益生元纤维会改变微生物组,本研究旨在了解益生元纤维在 PD 患者中的应用价值。最初的实验表明,用益生元纤维发酵 PD 患者的粪便会增加有益代谢物(短链脂肪酸,SCFA)的产生,并改变微生物群,表明 PD 微生物群有能力对益生元产生有利的反应。随后,对新诊断的、未用药的(n=10)和接受治疗的 PD 参与者(n=10)进行了一项开放标签、非随机研究,评估了 10 天益生元干预的影响。结果表明,益生元干预在 PD 参与者中耐受良好(主要结果)且安全(次要结果),并与微生物群、SCFA、炎症和神经丝轻链的有益生物学变化相关。探索性分析表明对临床相关结果有影响。这项概念验证研究为 PD 患者使用益生元纤维进行安慰剂对照试验提供了科学依据。ClinicalTrials.gov 标识符:NCT04512599。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/750ee7237454/41467_2023_36497_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/30534e78454a/41467_2023_36497_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/f2367d0d81bd/41467_2023_36497_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/f45207f565b6/41467_2023_36497_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/750ee7237454/41467_2023_36497_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/30534e78454a/41467_2023_36497_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/f2367d0d81bd/41467_2023_36497_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/f45207f565b6/41467_2023_36497_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ee5/9938876/750ee7237454/41467_2023_36497_Fig4_HTML.jpg

相似文献

1
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants.一项针对小队列帕金森病参与者的益生元纤维干预的开放性、非随机研究。
Nat Commun. 2023 Feb 18;14(1):926. doi: 10.1038/s41467-023-36497-x.
2
Effects of Resistant Starch on Symptoms, Fecal Markers, and Gut Microbiota in Parkinson's Disease - The RESISTA-PD Trial.抗性淀粉对帕金森病症状、粪便标志物和肠道微生物群的影响 - RESISTA-PD 试验。
Genomics Proteomics Bioinformatics. 2022 Apr;20(2):274-287. doi: 10.1016/j.gpb.2021.08.009. Epub 2021 Nov 25.
3
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
4
Short-Chain Fatty Acid Production by Gut Microbiota from Children with Obesity Differs According to Prebiotic Choice and Bacterial Community Composition.肠道微生物群产生的短链脂肪酸根据益生菌选择和细菌群落组成在肥胖儿童中存在差异。
mBio. 2020 Aug 11;11(4):e00914-20. doi: 10.1128/mBio.00914-20.
5
Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study.益生菌 UG1601 可减轻与肠道菌群相关的便秘相关事件:一项随机安慰剂对照干预研究。
World J Gastroenterol. 2019 Oct 28;25(40):6129-6144. doi: 10.3748/wjg.v25.i40.6129.
6
Prebiotics and Community Composition Influence Gas Production of the Human Gut Microbiota.益生元和群落组成影响人体肠道微生物群的气体生成。
mBio. 2020 Sep 8;11(5):e00217-20. doi: 10.1128/mBio.00217-20.
7
Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease.缺乏益生元纤维和通过肠道代谢物感应受体的信号不足会导致心血管疾病。
Circulation. 2020 Apr 28;141(17):1393-1403. doi: 10.1161/CIRCULATIONAHA.119.043081. Epub 2020 Feb 25.
8
Microbiota responses to different prebiotics are conserved within individuals and associated with habitual fiber intake.个体内不同的益生元对微生物组的反应是保守的,并且与习惯性纤维摄入有关。
Microbiome. 2022 Jul 29;10(1):114. doi: 10.1186/s40168-022-01307-x.
9
Maternal prebiotic supplementation during pregnancy and lactation modifies the microbiome and short chain fatty acid profile of both mother and infant.母亲在妊娠和哺乳期补充益生元会改变母亲和婴儿的微生物组和短链脂肪酸谱。
Clin Nutr. 2024 Apr;43(4):969-980. doi: 10.1016/j.clnu.2024.02.030. Epub 2024 Mar 1.
10
Fermentation properties and potential prebiotic activity of Bimuno® galacto-oligosaccharide (65 % galacto-oligosaccharide content) on in vitro gut microbiota parameters.Bimuno®低聚半乳糖(半乳糖低聚糖含量为65%)对体外肠道微生物群参数的发酵特性及潜在益生元活性
Br J Nutr. 2016 Aug;116(3):480-6. doi: 10.1017/S0007114516002269. Epub 2016 Jun 8.

引用本文的文献

1
Microbiome Engineering for Biotherapeutic in Alzheimer's Disease Through the Gut-Brain Axis: Potentials and Limitations.通过肠-脑轴进行阿尔茨海默病生物治疗的微生物组工程:潜力与局限
Int J Mol Sci. 2025 Jun 2;26(11):5351. doi: 10.3390/ijms26115351.
2
The Role of Inflammation in Neurodegenerative Diseases: Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis.炎症在神经退行性疾病中的作用:帕金森病、阿尔茨海默病和多发性硬化症。
Int J Mol Sci. 2025 May 28;26(11):5177. doi: 10.3390/ijms26115177.
3
The Role of Nutraceuticals and Functional Foods in Mitigating Cellular Senescence and Its Related Aspects: A Key Strategy for Delaying or Preventing Aging and Neurodegenerative Disorders.

本文引用的文献

1
Role of the gut microbiota in the development of various neurological diseases.肠道微生物群在各种神经疾病发展中的作用。
Neurologia (Engl Ed). 2022 Jul-Aug;37(6):492-498. doi: 10.1016/j.nrleng.2019.03.026. Epub 2021 May 25.
2
Gut-Brain Axis as a Pathological and Therapeutic Target for Neurodegenerative Disorders.肠脑轴作为神经退行性疾病的病理和治疗靶点。
Int J Mol Sci. 2022 Jan 21;23(3):1184. doi: 10.3390/ijms23031184.
3
Microbes and Parkinson's disease: from associations to mechanisms.微生物与帕金森病:从关联到机制
营养保健品和功能性食品在减轻细胞衰老及其相关方面的作用:延缓或预防衰老及神经退行性疾病的关键策略。
Nutrients. 2025 May 28;17(11):1837. doi: 10.3390/nu17111837.
4
Microecologics and Exercise: Targeting the Microbiota-Gut-Brain Axis for Central Nervous System Disease Intervention.微生态与运动:针对微生物群-肠-脑轴进行中枢神经系统疾病干预
Nutrients. 2025 May 23;17(11):1769. doi: 10.3390/nu17111769.
5
The emerging role of microbiota derived SCFAs in neurodegenerative disorders.微生物群衍生的短链脂肪酸在神经退行性疾病中的新作用。
Brain Behav Immun Health. 2025 May 7;46:101012. doi: 10.1016/j.bbih.2025.101012. eCollection 2025 Jul.
6
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis prospective.来自一项前瞻性荟萃分析的帕金森病肠道微生物群中的促炎和消耗GABA的细菌。
NPJ Parkinsons Dis. 2025 Jun 3;11(1):145. doi: 10.1038/s41531-025-00950-z.
7
The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.肠道微生物群作为癌症免疫治疗的靶点:药物开发的机遇与挑战
Nat Rev Drug Discov. 2025 Jun 2. doi: 10.1038/s41573-025-01211-7.
8
The gut-brain axis in early Parkinson's disease: from prodrome to prevention.早期帕金森病中的肠-脑轴:从前驱症状到预防
J Neurol. 2025 May 21;272(6):413. doi: 10.1007/s00415-025-13138-5.
9
Role of the Intestinal Microbiota in the Molecular Pathogenesis of Atypical Parkinsonian Syndromes.肠道微生物群在非典型帕金森综合征分子发病机制中的作用
Int J Mol Sci. 2025 Apr 22;26(9):3928. doi: 10.3390/ijms26093928.
10
Effects of enteral nutrition in stroke: an updated review.肠内营养对中风的影响:最新综述。
Front Nutr. 2025 Mar 31;12:1510111. doi: 10.3389/fnut.2025.1510111. eCollection 2025.
Trends Microbiol. 2022 Aug;30(8):749-760. doi: 10.1016/j.tim.2022.01.004. Epub 2022 Feb 7.
4
Quantitative analysis of short-chain fatty acids in human plasma and serum by GC-MS.GC-MS 法测定人血浆和血清中的短链脂肪酸
Anal Bioanal Chem. 2022 Jun;414(15):4391-4399. doi: 10.1007/s00216-021-03785-8. Epub 2022 Jan 29.
5
Regulation of common neurological disorders by gut microbial metabolites.肠道微生物代谢产物对常见神经紊乱疾病的调控。
Exp Mol Med. 2021 Dec;53(12):1821-1833. doi: 10.1038/s12276-021-00703-x. Epub 2021 Dec 2.
6
Cross-Sectional Study on the Gut Microbiome of Parkinson's Disease Patients in Central China.中国中部帕金森病患者肠道微生物群的横断面研究
Front Microbiol. 2021 Sep 28;12:728479. doi: 10.3389/fmicb.2021.728479. eCollection 2021.
7
Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier.肠道上皮屏障的炎症与微生物群相关调节
Front Nutr. 2021 Sep 13;8:718356. doi: 10.3389/fnut.2021.718356. eCollection 2021.
8
Parkinson's Disease and Gut Microbiota.帕金森病与肠道微生物群
Ann Nutr Metab. 2021;77 Suppl 2:28-35. doi: 10.1159/000518147. Epub 2021 Sep 9.
9
Gut brain axis: an insight into microbiota role in Parkinson's disease.肠脑轴:深入了解微生物群在帕金森病中的作用
Metab Brain Dis. 2021 Oct;36(7):1545-1557. doi: 10.1007/s11011-021-00808-2. Epub 2021 Aug 9.
10
Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease.帕金森病患者肠道炎症和肠道屏障通透性的血清及粪便标志物升高。
Front Neurosci. 2021 Jun 18;15:689723. doi: 10.3389/fnins.2021.689723. eCollection 2021.